中新网北京1月20日电 (记者 庞无忌)1月20日，自然资源部召开新闻发布会，发布了第一批《支持新产 业新业态发展的规划和土地政策创新案例集》(以下简称《案例集》)，推广北京、上海、杭州、广州、 深圳、南京、成都、西安、大连、湘潭、株洲等城市的19个案例的典型经验。 据介绍，这些案例均选自全国各地基层一线的鲜活实践，汇集了近期各地在优化规划调整及用途转换规 则、支持土地兼容复合利用、丰富土地配置方式、优化确权登记服务、强化监测评估等方面的智慧探索 与应用。 为了将政策转化为看得懂、学得会、用得上的"工具书"，《案例集》从案例背景、政策依据、创新举措 点、实施成效等方面提炼先进做法，配以简洁的图文讲解，以便各地"对照模板—借鉴做法—解决问 题"。 总体来看，《案例集》集中呈现了各地比较有代表性的创新实践。 二是土地兼容复合利用方面的创新。有关案例呈现出相关地区通过在"存量"和"效率"上做文章，激发新 增长点。如南京市通过盘活存量闲置地、弹性供给公共空间，从明确规划准入条件、引导绿色建造方 式、构建全周期服务机制等方面，将100余亩空闲地打造为江心洲E3PARK体育公园，成为竞技训练、 市民休闲、文旅打卡于一体的 ...

新产业公告，近日，公司梅毒螺旋体抗体检测试剂盒（磁微粒化学发光法）获得了由欧盟公告机构-T V 南德意志集团签发的IVDR CE最高风险等级Class D认证证书。 ...

新产业1月20日公告，公司肌红蛋白测定试剂盒（胶乳免疫比浊法）获得广东省药品监督管理局颁发的 《医疗器械注册证》。 本试剂盒用于体外定量测定人血清或血浆中的肌红蛋白含量。临床上用于心肌 梗死的辅助诊断。以上试剂新产品医疗器械注册证的取得，丰富了公司生化检测产品中"心血管及心肌 标志物"项目类别，将对公司发展具有正面影响，但对近期的生产经营和业绩不会产生重大影响｡ ...

证券代码：300832 证券简称：新产业 公告编号：2026-004 深圳市新产业生物医学工程股份有限公司 关于公司产品获得 IVDR CE 认证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 新的欧盟体外诊断医疗器械法规（IVDR, EU 2017/746）替代原欧盟体外诊 断医疗器械指令（IVDD, 98/79/EC）对欧盟市场的体外诊断医疗器械进行管理。 截至目前，公司累计213项化学发光试剂产品、67项生化试剂产品获得IVDR CE 认证。 根据欧盟体外诊断医疗器械法规的规定，本次获得IVDR CE认证的产品已经 具备进入欧盟市场的必要条件，后续将进一步增强公司产品的综合竞争力，对公 司未来的经营将产生积极影响。上述产品实际销售情况取决于未来市场推广效果， 公司目前尚无法预测其对公司未来业绩的影响，敬请广大投资者注意投资风险。 特此公告。 深圳市新产业生物医学工程股份有限公司 董事会 2026 年 1 月 20 日 1 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）梅毒 螺旋体抗体检测试剂盒（磁微粒化学发光法）获得了由欧盟公告机 ...

关于获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，深圳市新产业生物医学工程股份有限公司（以下简称"公司"）收到 了广东省药品监督管理局颁发的 1 项《医疗器械注册证》。具体情况如下： | | | 粤械注准 | | 年 | 月 | 日至 | 本试剂盒用于体外定量测 定人血清或血浆中的肌红 | | --- | --- | --- | --- | --- | --- | --- | --- | | 盒（胶乳免疫比浊 | Ⅱ类 | | 2026 | 01 | | 16 | | | 法） | | 20262400080 | 2031 | 年 01 | 月 | 日 15 | 蛋白含量。临床上用于心 | | 产品名称 肌红蛋白测定试剂 | 注册 分类 | 注册证编号 | | | 注册证有效期 | | 适用范围 肌梗死的辅助诊断。 | 证券代码：300832 证券简称：新产业 公告编号：2026-003 深圳市新产业生物医学工程股份有限公司 二、对公司的影响及风险提示 深圳市新产业生物医学工程股份有限公司 董事会 2026 年 1 月 20 ...

在国家加快培育新质生产力的战略背景下，战略性新兴产业已成为央企探索"第二增长曲线"的核心战场。 近期，中智咨询研究并发布了 《央企控股A股上市公司战新产业布局和模式路径比较研究报告》（以下简称《报告》）。 文末可限时免费下载报告 | 样本构成分析 | минания как компании в каминика и в правини в макен и композиции на каснив мона. | 03 | | --- | --- | --- | | 经营情况分析 | КОЖЕНИЕ РОДЕНИЕ СЕРБА ПРЕЗИЕ ПЛЕН Е ПРОДИТЕЛ В ОД ПОСОДИ И КОЛЕНИЕ ОД И КОЛЕНИЯ НА ОСОДНИ- SALE PRODUCT CASS CONSTITUTION CONSULTION CONSULTION CONSULTION CONSULTION CONSULTION OF C | 06 | | 10 | | --- | | CHANDER CONSECT POST CONSULTION CONCERT COLLECTION COLLECTION ...

1月20日，自然资源部召开新闻发布会，发布了第一批《支持新产业新业态发展的规划和土地政策创新 案例集》（以下简称《案例集》），推广北京、上海、杭州、广州、深圳、南京、成都、西安、大连、 湘潭、株洲等城市的19个案例的典型经验。据介绍，这些案例均选自全国各地基层一线的鲜活实践，汇 集了近期各地在优化规划调整及用途转换规则、支持土地兼容复合利用、丰富土地配置方式、优化确权 登记服务、强化监测评估等方面的智慧探索与应用。鼓励各地主动谋划创新举措，探索灵活、高效的资 源配置方式，形成"一地创新、多地收益"的良性循环，推动空间利用模式从"增量扩张"向"存量挖潜"、 从"刚性管控"到"弹性适配"转变，实现规划和土地政策从管制思维向经营思维转变，进一步释放和扩大 政策综合效能。 ...

Core Viewpoint - The company, New Industry Biomedical Engineering Co., Ltd., has experienced a decline in stock price and a mixed financial performance, with a slight increase in revenue but a significant decrease in net profit [1][2]. Group 1: Stock Performance - On January 20, the stock price of New Industry fell by 2.05% to 56.76 CNY per share, with a trading volume of 112 million CNY and a turnover rate of 0.29%, resulting in a total market capitalization of 44.597 billion CNY [1]. - Year-to-date, the stock price has increased by 0.91%, but it has decreased by 4.96% over the last five trading days, 3.80% over the last 20 days, and 8.32% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 3.428 billion CNY, representing a year-on-year growth of 0.39%, while the net profit attributable to shareholders was 1.205 billion CNY, reflecting a year-on-year decrease of 12.92% [2]. - Cumulatively, since its A-share listing, the company has distributed a total of 3.86 billion CNY in dividends, with 2.357 billion CNY distributed over the last three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per shareholder, which is an increase of 18.87% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 26.4824 million shares, an increase of 4.2383 million shares from the previous period [3].

Summary of China Healthcare Conference Call Industry Overview - **Industry**: China Healthcare - **Survey**: AlphaWise survey conducted with 80 hospital executives in November 2025, focusing on hospital capital expenditures (capex), procedure volumes, and brand preferences for 2026 [1][26] Key Findings Hospital Capex Outlook - **Cautiously Optimistic**: 59% of hospital executives expect higher capex in 2026, up from 43% in 2025, but still below 85% in 2024 [3][51] - **Expected Growth**: Average capex growth projected at 4.7% YoY for 2026, compared to 3.0% for 2025 [3][51] - **Actual Growth in 2025**: Estimated capex growth for 2025 was 5.8% YoY, indicating better-than-expected performance [3][51] - **Key Drivers**: Hospital surplus (69%), patient demand (50%), and local fiscal budgets (44%) are primary factors influencing capex decisions [31] Equipment Spending Trends - **Top Equipment Categories**: Surgical and soft endoscopes expected to see the highest unit growth at 26% and 16% respectively, followed by CT, ultrasound, and CLIA analyzers with high-teens growth [32][93] - **AI and Digitization**: AI, digitization, and cloud capabilities are the top investment priorities, with 84% of executives planning to increase spending in these areas [33][78] Brand Preferences and Market Dynamics - **Domestic Brands**: Mindray and United Imaging maintain strong positions in brand preference, with Mindray expected to gain share in surgical endoscopes and ultrasound [36][38] - **Foreign Brands**: Siemens Healthineers, GE Healthcare, and Philips show mixed performance, with potential share losses due to domestic competition [17][19][20] - **Market Shifts**: United Imaging is expected to gain significant share in CT and MR equipment, while Mindray is anticipated to strengthen its position in various categories [38] Pricing and Procurement - **Pricing Pressures**: Continuous pricing pressure expected in clinical testing, negatively impacting the IVD segment [10][42] - **Procurement Changes**: Increased expectations for centralized procurement and shorter tender cycles, which could lead to downward pricing pressures [30][61][62] Procedure Volume Expectations - **Moderating Growth**: Only 17% of executives expect growth in procedure volumes, down from 31% in the previous year, primarily due to budget constraints [39] - **Specialty Procedures**: Expected growth across major specialties is clustered in the mid-single-digit range, indicating stable demand [40] Stock Implications - **Positive Outlook for Certain Companies**: - **Mindray**: Expected to recover to positive revenue growth in 2026 due to stable capex environment [11] - **United Imaging**: Positioned to benefit from high-end imaging demand [12] - **APT Medical**: Anticipated to capture growth in cardiac ablation procedures [14][15] - **Zylox-Tonbridge**: Expected to see growth in neuro and peripheral intervention procedures [16] Risks and Challenges - **Market Uncertainty**: Hospital executives express caution regarding capex decisions, with procurement timing expected to be back-loaded into the second half of 2026 [68] - **Regulatory Pressures**: Ongoing regulatory scrutiny and tighter budgets continue to pose challenges for lower-tier hospitals [56] Conclusion The 2026 outlook for the China healthcare sector is cautiously optimistic, with expected growth in hospital capex and a focus on advanced medical technologies. However, challenges such as pricing pressures and market competition from domestic players remain significant factors influencing the landscape.

Core Insights - Wenzhou, known as the "capital of China's private economy," is transitioning towards a trillion-level economic scale, focusing on new growth points and industrial transformation [1] Group 1: Offshore Wind Power Development - Wenzhou is accelerating the development of deep-sea offshore wind power, with 17 projects planned and a capacity exceeding 20 million kilowatts, accounting for over 50% of the province's total [7] - The deep-sea wind power base in Wenzhou is set to deliver over 50 large offshore wind turbines and complete over 100 overseas orders by 2025 [1][3] Group 2: Manufacturing Investment Growth - Manufacturing investment in Wenzhou increased by 23.9% year-on-year from January to November 2025, driven by significant project implementations [5] Group 3: Artificial Intelligence and Data Integration - Wenzhou is leveraging data elements to support the development of its artificial intelligence industry, with plans to create a 100 billion-level AI industry cluster by 2027 [10] - The city has developed 50 high-quality datasets across various fields, including healthcare and industrial manufacturing, to support the training of vertical AI models [10] Group 4: Traditional Industry Transformation - The automotive and motorcycle parts industry in Wenzhou saw an increase of nearly 20% in value added from January to November 2025, showcasing its ability to maintain growth during transformation [12][21] - Traditional automotive parts are evolving towards high-end and intelligent upgrades, with a complete industrial chain being revitalized in Wenzhou [19] Group 5: Technological Advancements - Investment in technology research and development is creating new growth drivers for traditional industries, with automotive parts companies supplying over 100 vehicle models and producing more than 5,000 product varieties [21]